<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35950985</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5775</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>The Permanente journal</Title><ISOAbbreviation>Perm J</ISOAbbreviation></Journal><ArticleTitle>Stage IIA Skin Melanoma Treatment With ECHO-7 Oncolytic Virus Rigvir.</ArticleTitle><Pagination><StartPage>139</StartPage><EndPage>144</EndPage><MedlinePgn>139-144</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7812/TPP/21.232</ELocationID><Abstract><AbstractText>Melanoma is a global problem due to the rising numbers of skin melanoma cases. Current treatment guidelines for patients with stage IIA melanoma recommend only observation after surgery. In this report, the authors describe a patient with stage IIA skin melanoma treated with surgery and Rigvir virotherapy. Two years after the patient discovered a brown spot on the right cheek, surgery was indicated because the mass had started to ulcerate. Rigvir virotherapy was applied both before and after surgery. Observations made more than 7 years after surgery indicated no signs of disease progression. This case report illustrates an early treatment approach. Neoadjuvant treatment for early-stage melanoma is gaining more interest in both scientific and medical communities; therefore, the authors believe it is relevant to share their observations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Čēma</LastName><ForeName>Ingrīda</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Institute of Stomatology, Rīga Stradiņš University, Riga, Latvia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oncology Centre of Latvia, Rīga East University Hospital, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kleina</LastName><ForeName>Regīna</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medical faculty, Rīga Stradiņš University, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doniņa</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Oncology Centre of Latvia, Rīga East University Hospital, Riga, Latvia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Microbiology and Virology, Rīga Stradiņš University, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isajevs</LastName><ForeName>Sergejs</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, Rīga Eastern Clinical University Hospital, Riga, Latvia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Faculty of Medicine, University of Latvia, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zablocka</LastName><ForeName>Tatjana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, Rīga Eastern Clinical University Hospital, Riga, Latvia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Faculty of Medicine, University of Latvia, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasa</LastName><ForeName>Agnija</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>R&amp;D, Rigvir, Riga, Latvia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alberts</LastName><ForeName>Pēteris</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>R&amp;D, Rigvir, Riga, Latvia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Perm J</MedlineTA><NlmUniqueID>9800474</NlmUniqueID><ISSNLinking>1552-5767</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="Y">Melanoma</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050504" MajorTopicYN="Y">Oncolytic Viruses</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="Y">Skin Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000096142" MajorTopicYN="N">Melanoma, Cutaneous Malignant</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ECHO-7 virus</Keyword><Keyword MajorTopicYN="N">Rigvir</Keyword><Keyword MajorTopicYN="N">case report</Keyword><Keyword MajorTopicYN="N">melanoma</Keyword><Keyword MajorTopicYN="N">oncolytic virus</Keyword><Keyword MajorTopicYN="N">peritumoral administration</Keyword><Keyword MajorTopicYN="N">virotherapy</Keyword></KeywordList><CoiStatement><b>Conflicts of Interest:</b> Agnija Rasa and Pēteris Alberts are employees of Rigvir.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>11</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35950985</ArticleId><ArticleId IdType="pmc">PMC9683754</ArticleId><ArticleId IdType="doi">10.7812/TPP/21.232</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Cancer Research Fund International. Worldwide cancer data. Accessed
23 February 2022. https://www.wcrf.org/dietandcancer/worldwide-cancer-data</Citation></Reference><Reference><Citation>European Cancer Information System. Skin melanoma burden in EU-27. Accessed
23 February 2022. https://ecis.jrc.ec.europa.eu/pdf/factsheets/Melanoma_cancer_en.pdf</Citation></Reference><Reference><Citation>Coricovac D, Dehelean C, Moaca E-A, et al. . Cutaneous melanoma—A long road from experimental models to clinical outcome: A review. Int J Mol Sci. 2018;19(6):1566. 10.3390/ijms19061566</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19061566</ArticleId><ArticleId IdType="pmc">PMC6032347</ArticleId><ArticleId IdType="pubmed">29795011</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonardi GC, Candido S, Falzone L, Spandidos DA, Libra M. Cutaneous melanoma and the immunotherapy revolution (Review). Int J Oncol. 2020;57(3):609–618. 10.3892/ijo.2020.5088</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2020.5088</ArticleId><ArticleId IdType="pmc">PMC7384846</ArticleId><ArticleId IdType="pubmed">32582963</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberts P, Tilgase A, Rasa A, Bandere K, Venskus D. The advent of oncolytic virotherapy in oncology: The Rigvir® story. Eur J Pharmacol. 2018;837:117–126. 10.1016/j.ejphar.2018.08.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2018.08.042</ArticleId><ArticleId IdType="pubmed">30179611</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell L, Peng KW, Russell SJ, Diaz RM. Oncolytic viruses: Priming time for cancer immunotherapy. BioDrugs. 2019;33(5):485–501. 10.1007/s40259-019-00367-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-019-00367-0</ArticleId><ArticleId IdType="pmc">PMC6790338</ArticleId><ArticleId IdType="pubmed">31321623</ArticleId></ArticleIdList></Reference><Reference><Citation>Doniņa S, Strēle I, Proboka G, et al. . Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Melanoma Res. 2015;25(5):421–426. 10.1097/CMR.0000000000000180</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CMR.0000000000000180</ArticleId><ArticleId IdType="pmc">PMC4560272</ArticleId><ArticleId IdType="pubmed">26193376</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley DS, Barber MS, Kienle GS, et al. . CARE guidelines for case reports: Explanation and elaboration document. J Clin Epidemiol. 2017;89:218–235. 10.1016/j.jclinepi.2017.04.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2017.04.026</ArticleId><ArticleId IdType="pubmed">28529185</ArticleId></ArticleIdList></Reference><Reference><Citation>Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 7th ed. New York: Springer; 2010.</Citation></Reference><Reference><Citation>US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program . Common Terminology Criteria for Adverse Events (CTCAE) v4.03. June
14, 2010. Accessed
1 April 2018. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_40</Citation></Reference><Reference><Citation>Tseng WH, Martinez SR. Tumor location predicts survival in cutaneous head and neck melanoma. J Surg Res. 2011;167(2):192–198. 10.1016/j.jss.2010.10.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2010.10.008</ArticleId><ArticleId IdType="pmc">PMC3077472</ArticleId><ArticleId IdType="pubmed">21176922</ArticleId></ArticleIdList></Reference><Reference><Citation>Matheson JAH, Te Marvelde L, Mailer S, et al. . Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma. Melanoma Res. 2017;27(1):43–49. 10.1097/CMR.0000000000000302</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CMR.0000000000000302</ArticleId><ArticleId IdType="pubmed">27753732</ArticleId></ArticleIdList></Reference><Reference><Citation>Stenger M. No Survival Benefit With Complete Lymph Node Dissection vs Observation in Sentinel Node-Positive Melanoma. 2019. Accessed
21 October 2021. https://ascopost.com/news/october-2019/complete-lymph-node-dissection-vs-observation-in-sentinel-node-positive-melanoma</Citation></Reference><Reference><Citation>Faries MB, Thompson JF, Cochran AJ, et al. . Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–2222. 10.1056/NEJMoa1613210</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1613210</ArticleId><ArticleId IdType="pmc">PMC5548388</ArticleId><ArticleId IdType="pubmed">28591523</ArticleId></ArticleIdList></Reference><Reference><Citation>National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology. Melanoma. 2014 (Version 4). Accessed
8 July 2014. https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1492</Citation></Reference><Reference><Citation>National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology. Melanoma: Cutaneous. 2021 (Version 2). Accessed
10 August 2021. https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1492</Citation></Reference><Reference><Citation>Neoadjuvant T-VEC in High Risk Early Melanoma. ClinicalTrials.gov identifier: NCT04427306. Updated June 21, 2022. Accessed
23 September 2021. https://clinicaltrials.gov/ct2/show/NCT04427306</Citation></Reference><Reference><Citation>Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma. ClinicalTrials.gov identifier: NCT03757689. Updated May 23, 2022. Accessed
23 September 2021. https://clinicaltrials.gov/ct2/show/NCT03757689?term=NCT03757689&amp;draw=2&amp;rank=1</Citation></Reference><Reference><Citation>Neoadjuvant Atezolizumab in Cutaneous Melanoma. ClinicalTrials.gov identifier: NCT04020809. Updated January 14, 2022. Accessed
23 September 2021. https://clinicaltrials.gov/ct2/show/NCT04020809?term=NCT04020809&amp;draw=2&amp;rank=1</Citation></Reference><Reference><Citation>Garklāva R, Brūvere R, Vītoliņa L. Morphological and clinical parallels of changing rectal cancer during combined treatment (in Russian). In: Muceniece A, ed. Immunological Aspects of Viral Oncotropism. Riga, Latvia: Zinātne; 1979:114–120.</Citation></Reference><Reference><Citation>Brūvere R, Vītoliņa L, Garklāva R. Influence of a viral immunomodulator (Rigvir®) on cellular composition and topographic characteristics of the infiltration of the stroma of primary tumours of colorectal cancer (in Russian). Proc Latv Acad Sci. 1980;396:137–142.</Citation></Reference><Reference><Citation>Muceniece A, Venskus D. How to Assess Immunity - the Melanoma Model [Kā Vērtēt Imunitāti - Melanomas Modelis (in Latvian)]. Riga, Latvia: Ainas Mucenieces biedrība vēža imūnterapijas izstrādei sabiedriskā organizācija; 2007:117–121.</Citation></Reference><Reference><Citation>Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat Clin Pract Oncol. 2007;4(2):101–117. 10.1038/ncponc0736</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncponc0736</ArticleId><ArticleId IdType="pubmed">17259931</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribas A, Dummer R, Puzanov I, et al. . Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–1119. 10.1016/j.cell.2017.08.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.08.027</ArticleId><ArticleId IdType="pmc">PMC8034392</ArticleId><ArticleId IdType="pubmed">28886381</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkey SE, Thorne SH, Bartlett DL. Oncolytic virotherapy and the tumor microenvironment. Adv Exp Med Biol. 2017;1036:157–172. 10.1007/978-3-319-67577-0_11</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-67577-0_11</ArticleId><ArticleId IdType="pubmed">29275471</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington K, Freeman DJ, Kelly B, Harper J, Soria JC. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019;18(9):689–706. 10.1038/s41573-019-0029-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-019-0029-0</ArticleId><ArticleId IdType="pubmed">31292532</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Q, Chen N, Ge C, et al. . Prognostic value of tumor-infiltrating lymphocytes in melanoma: A systematic review and meta-analysis. Oncoimmunology. 2019;8(7):e1593806. 10.1080/2162402X.2019.1593806</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2019.1593806</ArticleId><ArticleId IdType="pmc">PMC6527267</ArticleId><ArticleId IdType="pubmed">31143514</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihm MC, Mulé JJ. Reflections on the histopathology of tumor-infiltrating lymphocytes in melanoma and the host immune response. Cancer Immunol Res. 2015;3(8):827–835. 10.1158/2326-6066.CIR-15-0143</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-15-0143</ArticleId><ArticleId IdType="pmc">PMC4527084</ArticleId><ArticleId IdType="pubmed">26242760</ArticleId></ArticleIdList></Reference><Reference><Citation>Haanen J. Converting cold into hot tumors by combining immunotherapies. Cell. 2017;170(6):1055–1056. 10.1016/j.cell.2017.08.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.08.031</ArticleId><ArticleId IdType="pubmed">28886376</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>